The sodium/glucose cotransport family SLC5

2004 ◽  
Vol 447 (5) ◽  
pp. 510-518 ◽  
Author(s):  
Eric Turk ◽  
Ernest M. Wright
2007 ◽  
Vol 50 (6) ◽  
pp. 963-970 ◽  
Author(s):  
Kátia Cylene Guimaraes ◽  
Sarah Rodrigues Hazelton ◽  
James Clyde Matthews ◽  
Kendall Carl Swanson ◽  
David Lee Harmon ◽  
...  

2018 ◽  
Vol 138 (3) ◽  
pp. 557-569 ◽  
Author(s):  
Vladimir Kepe ◽  
Claudio Scafoglio ◽  
Jie Liu ◽  
William H. Yong ◽  
Marvin Bergsneider ◽  
...  

Biochemistry ◽  
2004 ◽  
Vol 43 (41) ◽  
pp. 13175-13184 ◽  
Author(s):  
Ana Díez-Sampedro ◽  
Donald D. F. Loo ◽  
Ernest M. Wright ◽  
Guido A. Zampighi ◽  
Bruce A. Hirayama

1997 ◽  
Vol 21 (4) ◽  
pp. 185-191 ◽  
Author(s):  
Devendra I. Mehta ◽  
Karoly Horváth ◽  
Somchoke Chanasongcram ◽  
Ivor D. Hill ◽  
Pinaki Panigrahi

1991 ◽  
Vol 69 (7) ◽  
pp. 964-977 ◽  
Author(s):  
P. Vinay ◽  
J. Sénécal ◽  
J. Noël ◽  
C. Chirinian ◽  
M. C. Vinay ◽  
...  

The transport of glucose by canine thick ascending limbs (TAL) and inner medullary collecting ducts (IMCD) was studied using tubule suspensions and membrane vesicles. The uptake of D-[14C(U)]glucose by a suspension of intact TAL tubules was reduced largely by phloretin (Pt), moderately by phlorizin (Pz), and completely suppressed by a combination of both agents. A selective effect of Pz on the transport of [14C]α-methyl-D-glucoside, but not on 2-[3H]deoxyglucose, was also observed in TAL tubules. In contrast, glucose transport was unaffected by Pz but entirely suppressed by Pt alone in IMCD tubules. The metabolism of glucose was largely suppressed by Pt but unaffected by Pz in both types of tubules. Membrane vesicles were prepared from the red medulla and the white papilla or from TAL and IMCD tubules isolated from these tissues. Vesicle preparations from both tissues demonstrated a predominant carrier-mediated, sodium-independent, Pt- and cytochalasin B-sensitive glucose transport. Following purification of basolateral membrane on a Percoll gradient, the sodium-insensitive D-[14C(U)]glucose transport activity copurified with the activity of the basolateral marker Na+–K+ ATPase in both tissues. However, a small sodium-dependent and Pz-sensitive component of glucose transport was found in membrane vesicles prepared from the red medulla or from thick ascending limb tubules but not from the papilla nor collecting duct tubules. The kinetic analysis of the major sodium-independent processes showed that the affinity of the transporter for glucose was greater in collecting ducts (Km = 2.3 mM) than in thick ascending limbs (Km = 4.9 mM). We conclude that glucose gains access into the cells largely through a basolateral facilitated diffusion process in both segments. However a small sodium–glucose cotransport is also detected in membranes of TAL tubules. The transport of glucose presents an axial differentiation in the affinity of glucose transporters in the renal medulla, ensuring an adequate supply of glucose to the glycolytic inner medullary structures.Key words: basolateral membranes, tubules, medulla, thick ascending limbs, collecting ducts, glucose transport, phlorizin, phloretin, dog.


2019 ◽  
Vol 24 (5) ◽  
pp. 422-427 ◽  
Author(s):  
Aparna P. Sajja ◽  
Amit K. Dey ◽  
Avirup Guha ◽  
Youssef Elnabawi ◽  
Aditya A. Joshi ◽  
...  

There is a growing body of evidence that diabetes represents a significant and largely modifiable risk factor for cardiovascular disease (CVD). It is known to markedly increase the risk of CVD—with CVD accounting for 2 of every 3 deaths in patients with diabetes. It is suggested that once patients with diabetes develop clinical coronary disease, they have a grim prognosis. In 2008, the Food and Drug Association mandated the evidence of CV safety in any new diabetic therapy, leading to a multitude of large CV outcome trials to assess CV risk from these medications. However, several of these outcome trials with novel antidiabetic therapies have demonstrated not only safety but a clear and definite CV advantage in patients with type 2 diabetes. In this review, we discuss 2 relatively newer classes of diabetic drugs, sodium glucose cotransport 2 inhibitors and glucagon-like peptide 1 agonists, evaluate their efficacy in improving CV outcomes, and discuss the future of CV prevention with these agents.


Sign in / Sign up

Export Citation Format

Share Document